Biotoxtech, South Korea to Deploy Comprehensive Suite of Preclinical Study Management and SEND Software Solutions from Instem

Instem Technology Selected to Streamline Preclinical Operations, Improve Productivity and Ensure SEND Compliance at South Korea’s Largest Preclinical R&D Facility

CONSHOHOCKEN, PA – Business Wire, June 3, 2020 - Instem, a leading provider of IT solutions to the global life sciences market, announced today that South Korean Contract Research Organization (CRO), Biotoxtech Co., Ltd. (Biotoxtech) has purchased a comprehensive package of preclinical data collection, analysis and regulatory submissions management solutions to automate and optimize study related processes at its R&D facility in South Korea’s North Chungcheong Province.